Vaults engineered for hydrophobic drug delivery.

Area of Science:

• Biotechnology
• Nanomedicine
• Cell Biology

Background:

• Vault nanoparticles are large, conserved ribonucleoprotein complexes found in eukaryotes.
• Their hollow interior and nanocapsule structure make them promising for drug delivery.
• Existing methods struggle to deliver insoluble and toxic compounds like all-trans retinoic acid (ATRA).

Purpose of the Study:

• To engineer recombinant vaults for encapsulating hydrophobic therapeutic compounds.
• To evaluate the efficacy of ATRA-loaded vaults as a drug delivery system.
• To assess the cytotoxicity of ATRA-loaded vaults against cancer cells.

Main Methods:

• Engineering recombinant vaults using a vault-binding lipoprotein complex to form a lipid bilayer nanodisk.
• Encapsulating the hydrophobic drug all-trans retinoic acid (ATRA) within the nanodisks.
• Utilizing cryo-electron tomography (cryo-ET) to visualize the encapsulated complex within the vault.
• Testing the cytotoxicity of ATRA-loaded vaults on HepG2 hepatocellular carcinoma cells.

Main Results:

• Successful engineering of recombinant vaults capable of encapsulating ATRA.
• Cryo-electron tomography confirmed the sequestration of the vault-binding lipoprotein complex within the vault lumen.
• ATRA-loaded vaults demonstrated enhanced cytotoxicity against HepG2 cancer cells compared to controls.
• The vault nanocarrier protected the encapsulated ATRA from degradation.

Conclusions:

• Vault nanoparticles represent a viable and versatile platform for delivering therapeutic compounds.
• This study demonstrates the first successful use of vaults for encapsulating and delivering a hydrophobic drug.
• Engineered vaults show potential for improved cancer therapy, particularly for hepatocellular carcinoma.